Sodium Chloride Solution 0.9%

• Methotrexate treatment in hand osteoarthritis refractory to usual treatments Pending
  2022-502362-24-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
• Botulinum toxin injection after sternotomies to improve scar aspect and impact Pending
  2025-521290-14-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
• A study testing the medicine angiotensin II in patients of 0–17 years with a life-threateningly low blood pressure Pending
  2025-523750-14-00 Phase III 4 countries Paion Pharma GmbH
• Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting
  2025-522455-26-00 Phase I/II 3 countries TargED Biopharmaceuticals B.V.
• Evaluation of the efficacy of treatment with autovaccines vs antibiotic treatment in subjects with hip or knee prosthesis infections. Recruiting
  2024-520226-10-00 Phase III 1 country Instituto De Investigacion Marques De Valdecilla
• Novel treatment with botulinum toxin for erectile dysfunction unresponsive to conventional treatment Recruiting
  2024-514518-10-00 Phase II 1 country Clinica Universidad De Navarra
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 Phase I (FiH) 3 countries Moderna Inc.
• Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended
  2022-501707-27-01 Phase II/III 6 countries University Medical Center Utrecht
• A study to investigate the reactogenicity, safety, and immunogenicity of mRNA-1345 in pregnant women, and safety and immunogenicity in their… Ended
  2023-505359-37-00 Phase II 1 country Moderna Inc.
• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended
  2022-502022-41-00 Phase I (Other) 3 countries Moderna Inc.
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended
  2022-502888-38-00 Phase II 3 countries Eli Lilly & Co.
• An early-stage clinical study of a potential new medicine for patients with Netherton Syndrome Ended
  2022-502853-32-00 Phase I/II 1 country Daiichi Sankyo Inc.
• Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease… Ended
  2023-509105-72-00 Phase III 5 countries Pfizer Inc.
• Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended
  2024-517309-95-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg

Showing 1–14 of 14 trials